Bio-Techne (TECH) Q4 2025 Earnings Transcript

Bio-Techne reported Q4 fiscal 2025 revenue of $317 million, up 3% organically, with adjusted EPS rising to $0.53 from $0.49 and adjusted operating margin at 32%. Management announced the divestiture of Exosome Diagnostics to MDxHealth, expects about 100 bps of fiscal 2026 operating margin expansion, and continued strong large-pharma demand offset by low-single-digit growth in academia and biotech amid NIH, tariff, and MFN pricing uncertainty. The company also returned $112.5 million to shareholders via dividends and buybacks, while cash from operations totaled $98.2 million.

Analysis

The key read-through is that TECH is quietly de-risking the P&L while preserving optionality in the highest-quality parts of the portfolio. The Exosome divestiture is not just a margin event; it removes a structurally lower-value, lower-leverage asset and should raise the market’s confidence that management will keep recycling capital into consumables-heavy, higher-multiple businesses where renewal rates and pull-through are stronger.

The more important second-order effect is that management is implicitly telling you the current slowdown is a sentiment problem, not a demand-collapse problem. Large pharma is still spending, and the instrument franchise is proving it can win share when workflows move from discovery into regulated QA/QC — that is a better quality of growth than cyclical research tools. If that adoption holds, the implied mix shift could support margins even before top-line acceleration, because instruments seed consumable streams and lock in installed base economics.

The market is probably underestimating how much of the academic weakness is behavioral rather than budgetary. If purchasing is being delayed by uncertainty rather than destroyed, then a resolution on NIH/tariff/MFN headlines could create a sharp air-pocket rebound over 1-2 quarters, especially in reagents and spatial biology where project timing matters. The counterpoint is that China’s strength looks partly pulled forward, so investors should not extrapolate that growth rate into FY26.

The cleanest contrarian angle is that consensus is treating low-single-digit growth as a new normal, but management is effectively describing a temporary equilibrium. That makes the setup asymmetric: downside is limited by margin actions and capital returns, while upside can re-rate quickly if policy clarity restores customer ordering. The one thing that would break the thesis is a second leg down in biotech funding combined with a delayed NIH decision into calendar 2026, which would push the recovery out and keep the stock in a valuation purgatory.

Key Decisions for Investors

• Go long TECH on a 3-6 month horizon as a quality de-rating/re-rating setup: the downside is buffered by margin expansion and buybacks, while upside comes from any policy clarity on NIH/tariffs/MFN that releases deferred academic and biotech spend.
• Pair trade: long TECH / short a more NIH-exposed life science tools name with weaker consumables visibility (e.g., ILMN or a spatial biology-adjacent peer) for the next 2 quarters; TECH has better mix, better capital return, and less direct academic dependence than the market assumes.
• Buy TECH call spreads into any post-earnings consolidation: the near-term catalyst is the exosome close in fiscal Q1 2026 plus evidence that Q1 is flat-to-up on margin as promised; structure for modest upside, not a full re-rating.
• Avoid chasing MDXH on the headline alone: the acquired asset may be strategically useful, but integration risk and reimbursement/diagnostic execution matter more than the asset transfer; only consider after close and initial commercial commentary.
• Watch ABEO as a secondary beneficiary of validation in regulated QA/QC workflows; if TECH’s Simple Western adoption in cell/gene therapy keeps showing up in approval pathways, ABEO gets a credibility tailwind over 6-12 months.